Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Travere Therapeutics, Inc. (TVTX)

Travere Therapeutics CEO Eric Dube to step down; Bradley Campbell named successor

Neutral Impact 4 of 5 leadership Written later

Travere Therapeutics said CEO Eric Dube will step down as President, CEO and board member effective December 1, 2026, and Bradley L. Campbell, former CEO of Amicus Therapeutics, will succeed him in both roles on the same date. Dube will stay on as Executive Advisor through February 15, 2027, and his employment ends February 16, 2027, unless the two sides agree to an earlier date. The change is a planned leadership transition under agreements both parties signed on September 21, 2026.

Key points

  • Eric Dube's CEO and board roles end December 1, 2026; Bradley L. Campbell takes both roles that day.
  • Dube's employment is scheduled to end February 16, 2027, and he will serve as a consultant for up to 18 months after the resignation date.
  • Campbell's employment agreement sets a $1,000,000 base salary, a target bonus of 85% of base salary, and approximate equity grants of $8,250,000 in stock options and $8,250,000 in restricted stock units.
  • Dube will not be eligible for the 2027 cash bonus program and will receive no further stock awards, though existing awards keep vesting.

The filing

CompanyTravere Therapeutics, Inc. (TVTX)
Form8-K, current report
Filed with the SECSep 21, 2026, 4:10 PM ET
Accession number0001438533-26-000068

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 21, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.